Qurient

Innovation for
Unmet
Medical
Needs

Global Leader
of Network
R&D

Clinical & non-clinical
pipeline with
Global
standard

Notice

2024-06-19	큐리언트, ‘아드릭세티닙’ AML 환자 대상 IND 승인
2024-06-14	큐리언트 면역항암제 ‘아드릭세티닙’,희귀 혈액암 임상 IND 승인
2024-05-27	큐리언트, Q901 ASCO 초록 공개…안전성·약물반응 검증
2024-05-23	큐리언트, 우선심사권 걸린 '텔라세벡' 허가 임상 본격화
2024-05-22	큐리언트, 美 NCI와 연구 계약 "머크와 BMS도 거쳐간 블록버스터 등용문"

Company

Founded in 2008, Qurient takes a pioneering position in the newly emerging biotech industry in Korea. Qurient introduced a unique virtual biotech model, running R&D operations not only in clinical development phases, but also in early discovery research stage, named ‘Network R&D’ model.See More
Business philosophy

Innovation for unmet medical needs

Qurient’s mission is to provide innovation for unmet medical needs to help patients around the world. Through fulfilling the mission, Qurient will be able to create concrete value for its shareholders. See More
Pipeline

Qurient portfolio plan aims to achieve balanced innovation by strategic positioning of the R&D programs.See More
IR/PR

Dear Qurient shareholders

Qurient would like to share brief updates on current progress made on its portfolio programs. See More